CNS Stimulant Drugs Market Size, Share, Growth and Forecast to 2030 | Credence Research

NEW YORK - Feb. 10, 2024 - PRLog -- The latest market report published by Credence Research, Inc. The global demand for central nervous system (CNS) stimulant drugs market was valued at USD 5845.8 million in 2022 and is expected to reach USD 9317.31 million in 2030, growing at a CAGR of 6.00% between 2023 and 2030.

The Central Nervous System (CNS) stimulant drugs market has witnessed significant growth in recent years, driven by the increasing prevalence of neurological disorders, attention deficit hyperactivity disorder (ADHD), and the need for enhanced cognitive performance. CNS stimulant drugs play a pivotal role in treating these conditions, and their market has been expanding steadily as a result.

Market Size and Growth:

The global CNS stimulant drugs market has experienced remarkable growth, with projections showing continued expansion. Factors contributing to this growth include a rising awareness of neurological disorders, a surge in research and development efforts, and advancements in drug delivery technologies. As of 2022, the market was valued at over $10 billion, and it is anticipated to reach even higher figures by 2024.

Key Players:

Several pharmaceutical companies dominate the CNS stimulant drugs market, such as Shire Plc, Teva Pharmaceuticals, Novartis AG, and Johnson & Johnson. These companies are continually innovating and investing in research and development to introduce new drugs and improve existing ones, thereby expanding their market presence.

List of Companies Covered:

• GlaxoSmithKline Plc
• Johnson & Johnson Services Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Others

Browse the Full Report: https://www.credenceresearch.com/report/central-nervous-system-stimulant-drugs-market

Segmentation:

By Attention Deficit Hyperactivity Disorder (ADHD) Medications

• Methylphenidate-Based Medications
• Amphetamine-Based Medications

By Narcolepsy Medications

• Modafinil
• Armodafinil

By Depression and Bipolar Disorder Medications

• Bupropion
• Tricyclic Antidepressants

By Off-Label Uses

• Cognitive Enhancement

By Brands and Generics

• Brand-Name Medications
• Generic Medications

By Extended-Release Formulations

• Extended-Release Tablets/Capsules

By Dosage Forms

• Tablets
• Capsules
• Oral Solutions

By Delivery Methods

• Transdermal Patches
• Intranasal Formulations

By Pediatric and Adult Formulations

• Pediatric Dosages

By Adult Dosages Combination Therapies

• Combination of Stimulants and Non-Stimulants

By Regulatory Landscape

• FDA-Approved Medications
• Controlled Substances

By Emerging Pipeline

• Research and Development
• Novel Formulations

By Generic Competition

• Patent Expirations

By Patient Preferences

• Patient Adherence and Tolerability

By Region

• North America
• Europe
• Asia Pacific
• Rest of World